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PaclitaxelOsteosarcoma is the most common primary malignant tumor, and its treatments require more effective thera-
peutic approaches. Paclitaxel has a broad range of antitumor activities, including apoptosis-inducing effects.
However, themajority of tumors in patients with advanced cancer eventually develop chemoresistance. Connec-
tive tissue growth factor (CTGF) is a secreted protein that modulates the invasiveness of certain human cancer
cells by binding to integrins. However, the effect of CTGF in paclitaxel-mediated chemotherapy is unknown.
Here, we report that the expression of CTGF in osteosarcoma patients was signiﬁcantly higher than that of the
CTGF expression in normal bone tissues. Overexpression of CTGF increased the resistance to paclitaxel-
mediated cell apoptosis. In contrast, knockdown of CTGF expression by CTGF shRNA increased the chemothera-
peutic effect of paclitaxel. In addition, CTGF increased resistance to paclitaxel-induced apoptosis through upreg-
ulation of survivin expression. Moreover, the AMP-activated protein kinase (AMPK)-dependent nuclear factor
kappa B (NF-κB) pathway mediated paclitaxel-increased chemoresistance and survivin expression. In a mouse
xenograft model, overexpression of CTGF promoted resistance to paclitaxel. In contrast, knockdown of CTGF ex-
pression increased the therapeutic effect of paclitaxel in this model. In conclusion, our data indicate that CTGF
might be a critical oncogene of human osteosarcoma involved in resistance to paclitaxel treatment.
© 2014 Published by Elsevier B.V.1. Introduction
Osteosarcoma is the most common histological form of primary
bone cancer and the eighth most common form of childhood cancer. It
arises from the malignant transformation of mesenchymal cells, often
occurring during cell differentiation in the formation of osteoid and im-
mature bone [1,2]. Before and after surgical resection of osteosarcoma
tumors, patients usually undergo an aggressive chemotherapy regimen.
Improvements in chemotherapeutic regimens and surgical techniques
have resulted in a 5-year overall survival rate of 52–62% [3]. Paclitaxel
(Taxol® global to all pages)was reported to have cytotoxic activity against
many forms of leukemia and solid tumors, including chemotherapy-
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vier B.V.and non-small cell lung cancer, head and neck cancer, and osteosarcoma
[4]. However, tumors in most of the patients with late-stage cancer often
develop resistance to paclitaxel [5,6]. Recent trials have shown that the
overall survival rate of patients with osteosarcoma has reached its peak
with little or no improvement for conventional treatment modalities be-
cause of the development of osteosarcomaswith chemotherapeutic resis-
tance [7,8]. Therefore, it is important to understand the molecular
mechanisms that contribute to drug resistance of tumors, and to identify
novel therapeutic targets in human osteosarcoma.
Connective tissue growth factor (CTGF) is the secondmember of the
CCN family, also known as CCN2, and has important roles in many bio-
logical processes; CTGF is also thought to be involved in tumor cell pro-
liferation, migration, angiogenesis, and metastasis [9,10]. The role of
CTGF in normal tissue ﬁbrosis has been well studied [11]. On the other
hand, CTGF has also been identiﬁed as an oncogene in a variety of
cancers, including melanoma, chondrosarcoma, acute lymphoblastic
leukemia, and pancreatic cancer [12–14]. Clinically, CTGF expression
correlates with melanoma progression and metastasis. Inhibition of
CTGF, either genetically or with a speciﬁc anti-CTGF monoclonal anti-
body, signiﬁcantly inhibits the ability of human melanoma cells to
grow in the skin [15,16]. Furthermore, the role of CTGF in the
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ed in breast cancer [17] and ovarian cancer [18]. These observations
suggest that CTGF expression may be involved in the progression and
chemoresistance of human cancers.
A previous study has shown that paclitaxel interacts with microtu-
bules and induces apoptosis in various tumor cells [19]. Acquired resis-
tance to paclitaxel may be mediated by a number of proposed
mechanisms, including overexpression of P-glycoprotein, alterations
in tubulin, and aberrant signal transduction pathways inhibiting apo-
ptosis [5]. Survivin has been characterized as a member of the inhibitor
of apoptosis (IAP) protein family [20] and has been shown to be in-
volved in early events in the development of resistance following pacli-
taxel exposure [21]. High levels of expression of survivin in ovarian
cancer patients were signiﬁcantly associated with clinical resistance to
a paclitaxel/platinum-based treatment programs, and stable transfec-
tion with survivin cDNA in ovarian cancer cells caused a 4- to 6-fold in-
crease in cellular resistance to paclitaxel [22]. On the other hand,
survivin has been reported to be a useful target for assessing tumor
prognosis and the degree of malignancy in human osteosarcoma [23].
Therefore, survivin plays an important role in tumor prognosis and in
modulating paclitaxel-induced apoptosis in human cancers.
Although the role of CTGF in chemoresistance has been implicated in
some types of cancer cells, the effect of CTGF on paclitaxel-induced cell
apoptosis in human osteosarcomahas not been extensively studied. The
objective of this study was to determine the in vitro and in vivo efﬁcacy
of CTGF in the paclitaxel-induced chemoresistance in human osteosar-
coma cells. Our results suggest that CTGF increases the protein expres-
sion of survivin, which promotes cell viability and resistance to
paclitaxel-mediated cell death in human osteosarcoma cells.2. Materials and methods
2.1. Materials
Anti-rabbit and anti-mouse IgG-conjugated horseradish peroxidase,
rabbit polyclonal antibodies (speciﬁc for p65, IκBα), and mouse mono-
clonal antibodies (speciﬁc for CTGF, survivin, poly[ADP-ribose] poly-
merase [PARP], phosphorylated IκBα and α-tubulin) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Small interfering
RNAs (siRNAs) against survivin, AMPKα1 and AMPKα2 were from the
same supplier; an siRNA control in experiments using targeted siRNA
transfection consisted of a scrambled sequence that will not lead to
the speciﬁc degradation of any known cellularmRNA. Rabbit polyclonal
antibodies speciﬁc for AMPKα phosphorylated at Thr172, p65 phosphor-
ylated at Ser536, and AMPKα were purchased from Cell Signaling and
Neuroscience (Danvers, MA). Ara-A, compound C, TPCK, and PDTC
were purchased from Calbiochem (San Diego, CA, USA). Lipofectamine
2000 was purchased from Invitrogen (Carlsbad, CA, USA). Reporter
lysis buffer was purchased from Promega (Madison, WI, USA). Human
osteosarcoma tissue arrays were purchased from Biomax (Rockville,
MD, USA). All other chemicals were purchased from Sigma-Aldrich
(St. Louis, MO, USA).2.2. Cell culture
The human osteosarcoma cell lines (MG-63, U-2 OS, and HOS) were
purchased from the American Type Cell Culture Collection (Manassas,
VA, USA).MG-63 andHOS cellsweremaintained in Dulbecco'sModiﬁed
Eagle Medium (DMEM) supplemented with 20 mM HEPES and 10%
heat-inactivated FCS, 2mMglutamine, penicillin (100 U/ml), and strep-
tomycin (100 μg/ml) at 37 °C with 5% CO2. U-2 OS cells were main-
tained in McCoy's 5A medium, which was supplemented with 10%
FBS, penicillin (100 U/ml), and streptomycin (100 μg/ml) at 37 °C
with 5% CO2.2.3. Overexpression of CTGF with the pcDNA3.1-CTGF expression vector
The complete CTGF open reading frame was ampliﬁed by reverse
transcription (RT)-PCR. Subsequent PCR ampliﬁcation from RT
reaction products was performed in 0.2 mM dNTPs, 1.5 mM
MgCl2, 40 U/ml of Platinum® global to all pages Pfx DNA Polymerase
(Invitrogen, Groningen, The Netherlands), and 1 nmol of each PCR
primer, designed to amplify the full-length CTGF DNA (sense: CCAACC
ATGACCGCCGCCAG, and antisense: TCATGCCATGTCTCCGTACATCTTCC
TG). PCR products were puriﬁed from agarose gels using the Viogene
Gel/PCR DNA Isolation System (Viogene, CA, USA). The complete CTGF
was cloned into the topoisomerase-activated pcDNA3.1-TOPO vector
(Invitrogen Carlsbad, CA).
2.4. Immunohistochemical staining
Human osteosarcoma tissue arrays were deparafﬁnized with xylene
and rehydrated through addition of ethanol. Endogenous peroxidase
activity was blocked with 3% hydrogen peroxide in methanol for
10 min. Heat-induced antigen retrieval was carried out for all sections
in 0.01 M sodium citrate buffer, pH 6 at 95 °C for 25 min. Human
CTGF antibody was applied at a dilution of 1:200 and incubated at
4 °C overnight. The antibody-binding signal was detected using the
NovoLink Polymer Detection System (Leica Microsystems) and visual-
ized with the diaminobenzidine reaction. The sections were counter-
stained with hematoxylin. The immunohistochemistry results were
scored by taking into account the percentage of positive detection and
intensity of the staining. The intensity score was given as follows: 0,
no staining; 1,weakly positive; 2,moderately positive; 3 and 4, strongly
positive.
2.5. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay
Cell viability was determined by the MTT assay. Cells were plated in
96-well plates at a concentration of 2000 cells per well. After treatment
with paclitaxel, cultureswerewashedwith PBS. Next, 0.5 mg/ml ofMTT
solution was added to each well and incubated at 37 °C for 30 min. To
dissolve formazan crystals, culture medium was replaced with an
equal volume of DMSO. After the mixture was shaken at room temper-
ature for 10 min, absorbance of each well was determined at 550 nm
using a microplate reader (Bio-Tek, Winooski, VT, USA).
2.6. Colony formation assay
Cells were plated in 12-well plates at a concentration of 1 × 104 cells
per well. After treatment with paclitaxel for 48 h, cells were washed
with PBS and replaced with fresh medium. Cells were allowed to form
colonies for 14 days before being stained with crystal violet (0.4 g/l).
2.7. 4′-6-diamidino-2-phenylindole (DAPI) staining
Apoptotic nuclei were detected using DAPI staining. Cells were plat-
ed in 6-well plates at a concentration of 1 × 106 cells per well. After
being treated with paclitaxel at various concentrations for 48 h, cells
were washed with PBS, ﬁxed with 4% paraformaldehyde, and analyzed
via ﬂuorescence microscopy to assess chromatin condensation and
segregation.
2.8. TUNEL assay
A terminal deoxynucleotidyl transferase-mediated deoxyuridine tri-
phosphate nick end labeling (TUNEL) assay was also used to examine
cell apoptosis using the BD ApoAlert™ DNA Fragmentation Assay Kit.
Cells were incubated with paclitaxel for 24 h, trypsinized, ﬁxed with
4% paraformaldehyde, and permeabilized with 0.1% Triton-X-100 in
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bated with the reaction mixture for 60 min at 37 °C. The stained cells
were then analyzed with a ﬂow cytometery.
2.9. Caspase-3 activity assay
Caspase-3 activity was measured by the direct assay of caspase-3
enzyme activity in cell lysates using synthetic chromogenic substrate
(Ac-DEVD-pNA; substrate for caspase-3). Cell lysates were prepared
and incubated with anti-caspase-3. Immunocomplexes were incubated
with peptide substrate in assay buffer (100 mM NaCl, 50 mM 4-(2-
hydroxyethyl)-1-piperazine-ethanesulphonic acid [HEPES], 10 mM di-
thiothreitol, 1 mM EDTA, 10% glycerol, and 0.1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate [CHAPS], pH 7.4) for 2 h at
37 °C. The release of p-nitroaniline was monitored at 405 nm. Results
are the percent change in activity compared to an untreated control.
2.10. Western blot analysis
The cellular lysates were prepared as described previously [24].
Protein concentration was determined using the Thermo Scientiﬁc
Pierce BCA Protein Assay Kit (Thermo Fisher Scientiﬁc Inc., USA).
Proteins were resolved on SDS-PAGE and transferred to immobilon
polyvinyldiﬂuoride (PVDF) membranes. The blots were blocked
with 4% BSA for 1 h at room temperature and incubated with the pri-
mary antibodies for 1 h at room temperature. After 3 washes in tris-
buffered saline with 0.05% Tween 20 (TBS-Tween), the blots were
subsequently incubated with a donkey anti-rabbit or anti-mouse
peroxidase-conjugated secondary antibody for 1 h at room temper-
ature. The blots were visualized by enhanced chemiluminescence
using a Kodak X-OMAT LS ﬁlm (Eastman Kodak, Rochester, NY).
Quantitative data were obtained using a computing densitometer
and ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
2.11. Quantitative real-time PCR
Total RNA was extracted from osteosarcoma cells using a TRIzol kit
(MDBio Inc., Taipei, Taiwan). The reverse transcription reaction was
performed using 2 μg of total RNA that was reverse transcribed into
cDNA using an oligo (dT) primer. A volume of 100 ng total cDNA was
added per 25-μl reaction, along with sequence-speciﬁc primers and
Taqman® probes. Sequences for all target gene primers and probes
were purchased commercially (β-actinwas used as the internal control)
(Applied Biosystems). qPCR assays were carried out in triplicate using a
StepOnePlus sequence detection system. The cycling conditions were
10 min of polymerase activation at 95 °C, followed by 40 cycles at
95 °C for 15 s and 60 °C for 60 s. The threshold was set above the non-
template control background and within the linear phase of target
gene ampliﬁcation to calculate the cycle number atwhich the transcript
was detected (denoted as CT).
2.12. Transfection and reporter gene assay
Human osteosarcoma cells were co-transfected with 0.8 mg κB-
luciferase plasmid and 0.4 mg β-galactosidase expression vector. Cells
were grown to 80% conﬂuence in 12 well plates and were transfected
on the following day with Lipofectamine 2000 (LF2000). DNA and
LF2000 were premixed for 20 min and then applied to cells. After 24 h
transfection, the cells were then incubated with the indicated agents.
After 24 h incubation, the media were removed, and cells were washed
once with cold PBS. To prepare lysates, 100 ml reporter lysis buffer was
added to eachwell, and cells were scraped fromdishes. The supernatant
was collected after centrifugation at 13,000 rpm for 2 min. Aliquots of
cell lysates (20 ml) containing equal amounts of protein (20–30 mg)
were placed into wells of an opaque black 96-well microplate. An
equal volume of luciferase substrate was added to all samples, andluminescence was measured in a microplate luminometer. The value
of luciferase activity was normalized to transfection efﬁciency moni-
tored by the co-transfected β-galactosidase expression vector.
2.13. Murine xenograft experiments
To generate murine subcutaneous tumors, 1 × 106 osteosarcoma
cells were injected subcutaneously into the right ﬂanks of nude mice
(purchased from the National Science Council Animal Center, Taipei,
Taiwan). Four weeks after injection, the subcutaneous tumor size had
reached a diameter of approximately 1000 mm3, and the mice received
intraperitoneal (i.p.) injections of paclitaxel (20 mg/kg) twice a week
thereafter. Tumor volumes were calculated by the following formula:
length × width2 × π/6. All mice were manipulated in accordance with
the Animal Care and Use Guidelines of the China Medical University
(Taichung, Taiwan), under a protocol approved by the Institutional An-
imal Care and Use Committee.
2.14. Statistics
The values given are mean± SEM. The signiﬁcance of difference be-
tween the experimental groups and controls was assessed by Student's
t test. The difference was considered signiﬁcant if the p value was less
than 0.05.
3. Results
3.1. Overexpression CTGF cells increases chemotherapy resistance to
paclitaxel in human osteosarcoma
Previous studies have demonstrated that CTGF expression confers
resistance to chemotherapeutic agents in ovarian [18] and breast cancer
[17].Wehypothesized that CTGFmay also be involved in chemotherapy
resistance in osteosarcoma. First, we used immunohistochemical stain-
ing to detect CTGF expression in osteosarcoma patients. We found that
the expression of CTGF in osteosarcoma patients was signiﬁcantly
higher than that of the CTGF expression in normal bone tissues
(Fig. 1A and B). Next, we examined the relationship between CTGF ex-
pression and chemotherapy effects on human osteosarcoma. To this
end, the CTGF-overexpression cell lines MG-63/CTGF, HOS/CTGF, and U-
2 OS/CTGF cells were established. Using the MTT assay, we observed
that overexpression of CTGF protected the cells from paclitaxel-induced
growth inhibition (Fig. 1C–E). These results indicated that CTGF conferred
resistance to paclitaxel in human osteosarcoma cells. We next compared
chemoresistance after paclitaxel stimulation among 3 osteosarcoma cell
lines. We found that the U-2 OS cells were more resistant to paclitaxel
than that the MG-63 and HOS cells were (Supplementary Figure S1). In
addition, Western blotting showed that expression of CTGF was higher
in the U-2 OS cells than that in the MG-63 cells (Supplementary ﬁgure
S2). To conﬁrm that CTGF conferred resistance to paclitaxel treatment,
we created Stable U-2 OS cell lines expressing CTGF short hairpin RNA
(U-2 OS/CTGF shRNA) and control short hairpin RNA (U-2 OS/Control
shRNA). Using a colony-formation assay, we found that knockdown of
CTGF expression via CTGF shRNA in U-2 OS cells drastically decreased
colony-forming ability of the cells upon exposure to paclitaxel (Fig. 1F
andG). These data indicated that CTGF plays an important role in increas-
ing the resistance of osteosarcoma cells to paclitaxel.
3.2. CTGF promotes cell survival by inhibiting paclitaxel-induced apoptosis
Paclitaxel interacts with microtubules and induces apoptosis in
various tumor cells [19]. Exposing osteosarcoma cells to paclitaxel
has been shown to increase apoptosis in these cells [4]. Because
cleavage of the PARP protein can serve as amarker for cells undergo-
ing apoptosis [25], we used PARP expression, detected by Western
blotting, to determine whether CTGF-induced cell survival is
Fig. 1. CTGF increases resistance to paclitaxel-mediated cell death. (A) Immunohistochemistry of CTGF expression in normal bone and osteosarcoma tissues [normal (n= 7); IIb stage OS
(n=6); IIIb stageOS (n=7)]. (B)Quantitative data from the tissues shown inpanel A. (C–E) Cellswere treatedwith paclitaxel for 24 h, and the cell viabilitywas analyzed by using theMTT
assay. (F) U-2 OS cells were transfectedwith control or CTGF shRNA, and the expression of CTGFwas examined byWestern blotting. (G) Cells were treatedwith paclitaxel (10 μM) for 48 h
and then transferred to freshmedium. After culture for 14 days, the colonieswere stained by crystal violet. Each experimentwas done in triplicate. Results are expressed asmeans± S.E.M.
*, difference between the means of U-2 OS/CTGF shRNA group and the mean of U-2 OS/control shRNA group was statistically signiﬁcant at p b 0.05.
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litaxel treatment resulted in higher PARP cleavage in MG-63/vector,
HOS/vector, and U-2 OS/vector cells than that in cells overexpress-
ing CTGF. To further conﬁrm that CTGF-induced resistance is
mediated through inhibition of apoptosis, TUNEL staining, DAPI
staining, and caspase-3 activity assays were also used to detect cell
apoptosis in osteosarcoma cells. We again found that overexpres-
sion of CTGF signiﬁcantly decreased paclitaxel-mediated cell apo-
ptosis (Fig. 2B, D, and F). In contrast, decreased CTGF expression
promoted paclitaxel-induced apoptosis (Fig. 2C, E, and G). These
data conﬁrmed that CTGF-induced resistance to paclitaxel is medi-
ated through inhibition of apoptosis.3.3. Survivin is involved in CTGF-mediated chemoresistance
Survivin has been demonstrated to play a role in inhibiting both
caspase-dependent and independent apoptosis [26]. In glioblastoma
multiforme, high levels of CTGF mRNA are directly correlated with ad-
vanced tumor stage because CTGF can induce the expression of survivin
[27]. We found that the protein and mRNA expression of survivin in-
creased in CTGF-overexpressing cells (Fig. 3A and B). To determine
whether survivin is involved in the CTGF-mediated chemoresistance,
we pretreated cells with control or survivin siRNA for 48 h before pacli-
taxel treatment. As shown in Fig. 3C andD, CTGF-mediated resistance to
paclitaxel-induced cell death was signiﬁcantly inhibited in the survivin
Fig. 2. CTGF-induced resistance ismediated through inhibition of apoptosis. (A) Cells were treatedwith paclitaxel (10 μM) for 24 h, and the PARP expressionwas examined byWestern blot-
ting. (B–G) Cells were treated with paclitaxel (10 μM) for 24 h, and cell apoptosis was examined by using TUNEL analysis (B and C), a DAPI assay (D and E), and caspase 3 activity (F and G).
Each experiment was done in triplicate. Results are expressed as means ± S.E.M. *, difference between means and the mean of the control group was statistically signiﬁcant at p b 0.05.
850 H.-C. Tsai et al. / Biochimica et Biophysica Acta 1843 (2014) 846–854siRNA-transfected cells, but not in the control siRNA-transfected cells.
This result was conﬁrmed by observation in the TUNEL assay indicating
increased DNA fragmentation in the survivin siRNA-transfected cells
(Fig. 3D). These results indicated that survivin plays an important role
in CTGF-induced paclitaxel resistance in human osteosarcoma cells.
3.4. AMPK and NF-κB signaling pathways are involved in CTGF-mediated
survivin expression and chemoresistance
AMP-activated protein kinase (AMPK)-dependent nuclear factor
kappa B (NF-κB) activation has been reported tomediate survivin expres-
sion and cell death [28]. We therefore examined whether AMPK and NF-
κB pathways are involved in CTGF-mediated survivin expression and
chemoresistance. Stimulation of MG-63/CTGF cells with paclitaxel in-
creased AMPK and p65 phosphorylation (Fig. 4A). The activity of NF-κB
is primarily regulated by interaction with inhibitory IκB proteins, and
IκBα is the best-studiedmember of the IκB family of proteins anddisplaysall deﬁning characteristics of an NF-κB inhibitor [29]. We also found that
paclitaxel increased IκBα phosphorylation (Fig. 4A). In addition, the NF-
κB-luciferase activity was also increased after treatment with paclitaxel
time-dependently (Fig. 4B). Furthermore, pretreatment of cells with
AMPK inhibitors (Ara A or compound C), NF-κB inhibitor (PDTC), IκB pro-
tease inhibitor (TPCK) or NEMO-binding domain peptide (NBD peptide,
NF-κB selective inhibitor peptide) [30] decreased the CTGF-mediated
chemoresistance (Fig. 4C–F), suggesting that the AMPK andNF-κB signal-
ing pathwaysmediated CTGF-increased resistance to paclitaxel. There are
2 α-subunits (α1 and α2) of AMPK that contain different catalytic sites
[31]. To determine which AMPK catalytic subunit is involved in CTGF-
mediated chemoresistance, siRNA against AMPKα1 and AMPKα2 was
used. As shown in Fig. 4C and D, whereas transfection of cells with
AMPKα1 markedly reduced the CTGF-mediated chemoresistance, no
such effect was observed after transfecting cells with AMPKα2 siRNA.
Therefore, AMPKα1 but not AMPKα2 is involved in CTGF-promoted
chemoresistance to paclitaxel in humanosteosarcoma. To further conﬁrm
Fig. 3. Survivin is involved in CTGF-mediated chemoresistance. (A) Expression of survivin protein examined byWestern blotting and (B) expression of survivinmRNAmeasured by q-PCR.
(C and D) Cells were transfectedwith control or survivin siRNA. (C) Cell viability and apoptosis were analyzed by using theMTT assay and (D) TUNEL analysis. Each experimentwas done
in triplicate. Results are expressed as means ± S.E.M. *, difference between means and the mean of the control group and #, difference between means and the mean of the MG-63 cells
treated with paclitaxel group, which were statistically signiﬁcant at p b 0.05.
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mediated survivin protein expression, we pretreated MG-63/CTGF cells
with Ara A, compound C, PDTC, or TPCK abolished paclitaxel-increased
p65 phosphorylation and survivin expression (Fig. 4G). Therefore,
AMPK-dependent NF-κB activation is involved in CTGF-mediated
survivin expression and chemoresistance to paclitaxel in human osteo-
sarcoma cells.
3.5. CTGF confers drug resistance to paclitaxel in a mouse xenograft model
To determine whether CTGF is also involved in paclitaxel-increased
resistance in vivo, the nude mice xenograft model was used. The MG-
63/vector, MG-63/CTGF, U-2 OS/Control shRNA, or U-2 OS/CTGF
shRNA cells were injected into the ﬂanks of nude mice. After 45 days,
the mice were sacriﬁced, and tumor volume and weight were mea-
sured. Remarkably, CTGF overexpression in osteosarcoma cells induced
a 2.6-fold higher tumor volume and 2-fold higher tumor weight than
that in the control cells (Fig. 5A, C, and D). Knockdown of CTGF expres-
sion in U-2 OS cells increased the cytotoxic effect of paclitaxel and de-
creased the tumor weight (Fig. 5B, C, and D). The protein levels of
survivin in tumor tissues of these four groups were also measured.
Western blotting showed that the protein levels of CTGF and survivin
were signiﬁcantly higher in the CTGF-overexpressing group than
those in the control group. However, knockdown of CTGF expression
had contrasting results (Fig. 5E). These data provide in vivo evidence
supporting the hypothesis that CTGF is a potential oncogene that con-
tributes to anti-chemotherapeutic effects in human osteosarcoma.
4. Discussion and conclusions
Today, most patients with osteosarcoma are treated with conven-
tional treatment strategies. However, approximately 30% of these pa-
tients relapse, and only a few do not die [1]. This is because tumor
cells in osteosarcoma patients can develop resistance to chemotherapy
drugs. Therefore, it is important to identify potential targets for
preventing the development of osteosarcoma tumor resistance tochemotherapy drugs. Here, we have shown that overexpressing CTGF
in human osteosarcoma cells promotes the cells' survival through
inhibiting paclitaxel-induced apoptosis in vitro and in vivo. We also
found that upregulated expression of survivin-mediated through
AMPK-dependent NF-κB signaling pathways-plays a role in the CTGF-
promoted resistance to paclitaxel. Overall, our results suggest that
CTGF plays an important role in osteosarcomaprogression by increasing
the resistance of cancer cells to paclitaxel-based chemotherapy.
CTGF is amultifunctional signalingprotein involved in awide variety
of biological and pathological processes [32,33]. The role of CTGF in can-
cer remains controversial, however. In some studies, CTGF has been
shown to be a factor in improved survival in patients [34,35]. For exam-
ple, in colorectal cancer, patients showed better overall survival when
their tumors displayed higher CTGF expression. In chondrosarcoma pa-
tients, the expression of CTGF also correlates with survival rates in pa-
tients [36]. Moreover, in human lung adenocarcinoma, CTGF inhibits
metastasis and invasion [37]. However, in human rhabdomyosarcoma,
disrupting CTGF expression by using CTGF-neutralizing antibodies in-
creases apoptosis and inhibits angiogenesis [38]. CTGF also inhibits
cell growth in squamous cell carcinoma [39]. Thus, the relationship be-
tween CTGF proteins and cancer progression cannot be generalized
across different types of cancers. Our data have shown that the expres-
sion of CTGF protein was signiﬁcantly higher in human osteosarcoma
than that in normal tissues, suggesting that CTGF plays an important
role in tumor progression. Previous studies have showed that CTGF ex-
pression confers resistance to chemotherapeutic agents in breast cancer
[40] and ovarian cancer [18]. These observations are consistentwith our
results indicating that overexpressing CTGF in MG-63 cells (which nor-
mally have low CTGF, expression and are paclitaxel sensitive) directly
increases the resistance to paclitaxel-induced cell death. On the other
hand, knockdown of endogenous CTGF expression in U-2 OS cells
(which normally have high CTGF, drug-expression and are paclitaxel re-
sistant) sensitized cells to paclitaxel treatment. In this study, overex-
pression of CTGF has only signiﬁcantly reduced the effects of
paclitaxel, but not completely mitigated the effects. That means there
are other mechanisms also operating for the action of paclitaxel,
Fig. 4.AMPK and NF-κB signaling pathways are involved in CTGF-mediated chemoresistance and survivin expression. (A) Cells were treatedwith paclitaxel (10 μM) for the time intervals
indicated, and phosphorylation of AMPK, IκBα, p65 andα-tubulin were examined byWestern blotting. (B) Cells transiently transfected with NF-κB-luciferase plasmid for 24 h before in-
cubation with paclitaxel (10 μM) for 24 h. Luciferase activity was measured, and the results were normalized to the β-galactosidase activity. (C–F) Cells were pretreated with Ara A
(0.5 mM), compound C (10 μM), PDTC (10 μM), TPCK (10 μM), and NBD peptide (50 μg/ml), or were transfected with AMPKα1 and AMPKα2 siRNAs, followed by stimulation with pac-
litaxel for 24 h. Apoptosiswas assessed using theMTT assay (C and E) and TUNEL analysis (D and F). (G)MG-63/CTGF cellswere pretreatedwith Ara A, compound C, PDTC, or TPCK for 1 h;
this was followed by stimulation with paclitaxel for 24 h, and p65 phosphorylation and survivin expression were examined byWestern blotting. Each experiment was done in triplicate.
Results are expressed as means ± S.E.M. *, difference between means and the mean of the control group and #, difference between means and the mean of the MG-63 cells treated with
paclitaxel group, which were statistically signiﬁcant at p b 0.05.
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arrest andDNAdamage-inducible 45 alphaprotein (GADD45α), a stress
signal response gene involved in regulation of DNA repair and apopto-
sis, was signiﬁcantly induced in osteosarcoma cells after exposure to
paclitaxel [41]. RAIDD (RIP associated ICH-1/CED-3-homologous protein
with a death domain) is an apoptosis associate gene, was also found
lower expressed in osteosarcomamultidrug resistant cell line. Transfec-
tion of osteosarcoma multidrug resistant cell line with RAIDD reversed
the paclitaxel-mediated resistance [42]. Autophagy is one of another
mechanism that observed during paclitaxel-induced apoptosis in
Saos-2 osteosarcoma cells [43]. Therefore, GADD45α, RAIDD and au-
tophagy may play a role in CTGF-independent mechanism afterpaclitaxel treatment. However, this hypothesis needs further examina-
tion. In our mouse xenografts experiments, we observed that CTGF ex-
pression protects osteosarcoma cells from paclitaxel treatment, and
eliminating CTGF expression in cancer cells signiﬁcantly increases the
therapeutic effect of paclitaxel. These data indicate that CTGF plays an
important role in increasing the resistance of osteosarcoma cells to
paclitaxel.
It has been indicated that failure to activate the intrinsic apoptotic
program is one of a recognized mechanism of drug resistance [44]. In-
creasing evidence suggests that survivin increases telomerase activity
during the development of chemotherapy resistance and that survivin
plays a role in cancer metastasis [45–47]. Here, we found that
Fig. 5. CTGF increases resistance to paclitaxel in a nudemouse xenograftmodel. (A and B) Tumor growth curves of human osteosarcoma cells treatedwith paclitaxel for 45 days. (C) Tumor
weight measured after mice were sacriﬁced. (D) Representative photomicrographs of MG-63/vector, MG-63/CTGF, U-2 OS/Control shRNA, and U-2 OS/CTGF shRNA cells from nudemice.
(E) Western blotting analysis to determine the protein levels of CTGF, survivin, and α-tubulin (control) in tumor cells.
853H.-C. Tsai et al. / Biochimica et Biophysica Acta 1843 (2014) 846–854overexpressing CTGF increased the expression of survivin. In addition,
knockdown of survivin expression signiﬁcantly reduced CTGF-mediated
chemoresistance to paclitaxel. Previous studies have reported similar re-
sults indicating that direct or indirect inhibition of survivin decreases the
proliferation and cell viability of osteosarcoma cells [48]. In addition,
inhibiting survivin in HeLa cells promoted caspase-dependent cell
death [49]. Furthermore, shRNA-mediated inhibition of survivin expres-
sion in human SAOS2 osteosarcoma cells enhanced sensitivity of these
cells to cisplatin anddoxorubicin [50]. According to these results, survivin
is an important downstream effector of increased resistance against
chemotherapy-induced cell apoptosis in osteosarcoma cells, and CTGF
might confer paclitaxel resistance in osteosarcoma cells by increasing
survivin expression.
It has been reported that AMPK-dependent NF-κB activation is in-
volved in survivin expression and cell death [28]. In the current study,
we found that CTGF increased the expression of AMPK and p65 activa-
tion in osteosarcoma cells. Furthermore, inhibitors of AMPK and NF-κB
reversed the CTGF-mediated resistance to paclitaxel. AMPK contains
two α-subunits, which have different catalytic sites. Here we report
that transfection of cells with AMPKα1 but not with AMPKα2 siRNA
markedly blocked CTGF-induced chemoresistance. Therefore, AMPKα1
appears to be more important than AMPKα2 in the CTGF-mediated re-
sistance to paclitaxel. Furthermore, we also showed that AMPK and NF-
κB inhibitors abolished CTGF-induced p65 phosphorylation and
survivin expression. These results suggest that the AMPK-dependent
NF-κB signaling pathway is important for CTGF-induced survivin ex-
pression and chemoresistance to paclitaxel.
In conclusion, we have shown that overexpression of CTGF in os-
teosarcoma cells increased cell survival by inhibiting paclitaxel-
induced apoptosis. Our in vitro results and in vivo xenograft studies
showed that overexpression of CTGF signiﬁcantly increased tumor
cell survival, and that suppression of CTGF expression signiﬁcantly
increased the sensitivity of osteosarcoma cells to paclitaxel. Thus,
we conclude that CTGF might be a critical oncogene, and we believe
that these data support an investigation of CTGF as a strategic target
in osteosarcoma therapy.Conﬂict of interest statement
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